Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients

MLA

Noah Sorrelle, et al. “Phase II Trial of Clinical Activity and Safety of Ceritinib Combined with Stereotactic Ablative Radiotherapy (SABR) in Lung Adenocarcinoma Patients.” Journal of Clinical Oncology, vol. 38, May 2020, p. e21571. EBSCOhost, https://doi.org/10.1200/jco.2020.38.15_suppl.e21571.

APA

Noah Sorrelle, Samantha Mannala, Hak Choy, Rolf A. Brekken, Puneeth Iyengar, Jessica Saltarski, Kenneth D. Westover, Jonathan E. Dowell, Sawsan Rashdan, Hong Zhu, Robert Timmerman, David E. Gerber, Kasia Harrah, Randall S. Hughes, Saad A. Khan, & Laurin L. Priddy. (2020). Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients. Journal of Clinical Oncology, 38, e21571. https://doi.org/10.1200/jco.2020.38.15_suppl.e21571

Chicago

Noah Sorrelle, Samantha Mannala, Hak Choy, Rolf A. Brekken, Puneeth Iyengar, Jessica Saltarski, Kenneth D. Westover, et al. 2020. “Phase II Trial of Clinical Activity and Safety of Ceritinib Combined with Stereotactic Ablative Radiotherapy (SABR) in Lung Adenocarcinoma Patients.” Journal of Clinical Oncology 38 (May): e21571. doi:10.1200/jco.2020.38.15_suppl.e21571.